{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T11:32:32Z","timestamp":1786361552022,"version":"build-2736575974"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Globally, gonorrhea remains a common sexually transmitted infection that can lead to serious sexual and reproductive health complications if left untreated. Management has become more challenging due to the rapid progression of antimicrobial resistance in\n                      <jats:italic toggle=\"yes\">Neisseria gonorrhoeae<\/jats:italic>\n                      . Currently, ceftriaxone-based regimens continue to be the standard treatment; however, the sudden demand for new treatment options is highlighted by concerns regarding resistance, the requirement for intramuscular administration, and the declining effectiveness of azithromycin.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This review aims to evaluate the emerging role of zoliflodacin in the treatment of gonorrhea, with an emphasis on its potential to serve as a resistance-focused alternative, its oral administration, and its novel antimicrobial target.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A narrative literature search was conducted using PubMed, Google Scholar, and Scopus to identify relevant studies published between 2016 and 2026. Randomized clinical trials, systematic reviews, narrative reviews, and international guidelines from the WHO, ECDC, and CDC were included. Literature selection was guided by SANRA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A single 3-g oral dose of zoliflodacin appears to exhibit high microbiological cure rates for uncomplicated urogenital and rectal gonorrhea, and it is not less effective than ceftriaxone plus azithromycin for urogenital infections, according to Phase 2 and recent global Phase 3 clinical trials, which reported mild gastrointestinal side effects. Its mechanism of action provides limited evidence of resistance and is effective against multidrug-resistant\n                      <jats:italic toggle=\"yes\">Neisseria gonorrhoeae<\/jats:italic>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Zoliflodacin represents a potentially effective oral alternative to the current ceftriaxone-based regimen for gonorrhea. With routine observation and careful stewardship, these findings may contribute significantly to the expansion of future treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ms9.0000000000005136","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T22:00:14Z","timestamp":1778709614000},"page":"3404-3410","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Zoliflodacin for uncomplicated gonorrhea: clinical evidence and implications beyond ceftriaxone plus azithromycin"],"prefix":"10.1097","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2259-5635","authenticated-orcid":false,"given":"Aliza","family":"Ahmed","sequence":"first","affiliation":[{"name":"Department of Medicine and Surgery, Jinnah Sindh Medical University, Karachi, Sindh, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4088-3277","authenticated-orcid":false,"given":"Mubashira","family":"Noor","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, Jinnah Sindh Medical University, Karachi, Sindh, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6405-4868","authenticated-orcid":false,"given":"Yumna","family":"Shahzad","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, National Institute of Cardiovascular Diseases, Karachi, Sindh, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7779-0521","authenticated-orcid":false,"given":"Aleeza","family":"Abid","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, Jinnah Sindh Medical University, Karachi, Sindh, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6608-6708","authenticated-orcid":false,"given":"Muhammad Hassan","family":"Saeed","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, Jinnah Postgraduate Medical Centre, Karachi, Sindh, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6491-1404","authenticated-orcid":false,"given":"Ihsan","family":"Qamar","sequence":"additional","affiliation":[{"name":"Department of Medicine and Surgery, Spinghar Medical University, Kabul, Afghanistan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"R1-20260810","doi-asserted-by":"crossref","first-page":"682135","DOI":"10.3389\/fphar.2021.682135","article-title":"Pharmacodynamic evaluation of dosing, bacterial kill, and resistance suppression for zoliflodacin against Neisseria gonorrhoeae in a dynamic hollow fiber infection model","volume":"12","author":"Jacobsson","year":"2021","journal-title":"Front Pharmacol"},{"key":"R2-20260810","doi-asserted-by":"crossref","first-page":"7767","DOI":"10.3390\/jcm12247767","article-title":"Neisseria gonorrhoeae antimicrobial resistance: the future of antibiotic therapy","volume":"12","author":"Raccagni","year":"2023","journal-title":"J Clin Med"},{"key":"R3-20260810","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13756-020-00805-7","article-title":"Azithromycin resistant gonococci: a literature review","volume":"9","author":"Derbie","year":"2020","journal-title":"Antimicrob Resist Infect Control"},{"key":"R4-20260810","doi-asserted-by":"crossref","first-page":"1172589","DOI":"10.3389\/fphar.2023.1291885","article-title":"Pharmacodynamics of zoliflodacin plus doxycycline combination therapy against Neisseria gonorrhoeae in a gonococcal hollow-fiber infection model","volume":"14","author":"Jacobsson","year":"2023","journal-title":"Front Pharmacol"},{"key":"R5-20260810","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1093\/cid\/ciac043","article-title":"Management of Neisseria gonorrhoeae in the United States: summary of evidence from the development of the 2020 gonorrhea treatment recommendations and the 2021 Centers for Disease Control and Prevention sexually transmitted infection treatment guidelines","volume":"74","author":"Barbee","journal-title":"Clin Infect Dis"},{"key":"R6-20260810","first-page":"37\u201358","article-title":"Antimicrobial resistance in Neisseria gonorrhoeae and treatment of gonorrhea","volume":"1997","author":"Unemo","year":"2019","journal-title":"Methods Mol Biol"},{"key":"R7-20260810","doi-asserted-by":"crossref","first-page":"100624","DOI":"10.1016\/j.ijregi.2025.100624","article-title":"High susceptibility to the novel antimicrobial zoliflodacin among Neisseria gonorrhoeae isolates in eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme countries in three WHO regions, 2021-2024","volume":"15","author":"Jacobsson","year":"2025","journal-title":"IJID Regions"},{"key":"R8-20260810","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s44263-024-00087-w","article-title":"Recommendations for the optimal introduction of novel antibiotics to treat uncomplicated gonorrhoea in the face of increasing antimicrobial resistance: a case study with zoliflodacin","volume":"2","author":"Pascual","year":"2024","journal-title":"BMC Glob Public Health"},{"key":"R9-20260810","doi-asserted-by":"crossref","first-page":"e24427","DOI":"10.1002\/jcla.24427","article-title":"Mechanism of action, resistance, synergism, and clinical implications of azithromycin","volume":"36","author":"Heidary","year":"2022","journal-title":"J Clin Lab Anal"},{"key":"R10-20260810","doi-asserted-by":"crossref","first-page":"469\u2013527","DOI":"10.2165\/00003495-198427060-00001","article-title":"A review of its antibacterial activity, pharmacological properties and therapeutic use","volume":"27","author":"Richards","year":"1984","journal-title":"Drugs"},{"key":"R11-20260810","doi-asserted-by":"crossref","first-page":"486\u201388","DOI":"10.1016\/S1473-3099(18)30162-2","article-title":"Dual antimicrobial therapy for gonorrhoea: what is the role of azithromycin?","volume":"18","author":"Unemo","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"R12-20260810","doi-asserted-by":"crossref","first-page":"e351","DOI":"10.1016\/S1473-3099(24)00230-5","article-title":"Ceftriaxone resistance in Neisseria gonorrhoeae associated with the penA-60.001 allele in Hanoi, Viet Nam","volume":"24","author":"Adamson","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"R13-20260810","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.3390\/antibiotics11111480","article-title":"Tolerance to ceftriaxone in Neisseria gonorrhoeae: rapid induction in WHO P reference strain and detection in clinical isolates","volume":"11","author":"Balduck","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"R16-20260810","first-page":"1835\u201345","article-title":"Single-dose zoliflodacin (ETX0914) for treatment of urogenital gonorrhea","volume":"379","author":"Taylor","journal-title":"N Engl J Med"},{"key":"R17-20260810","doi-asserted-by":"crossref","first-page":"3071\u201382","DOI":"10.1021\/acsinfecdis.4c00438","article-title":"Interactions between Zoliflodacin and Neisseria gonorrhoeae Gyrase and Topoisomerase IV: enzymological Basis for Cellular Targeting","volume":"10","author":"Collins","year":"2024","journal-title":"ACS Infect Dis"},{"key":"R18-20260810","doi-asserted-by":"crossref","first-page":"3111\u201324","DOI":"10.1093\/jac\/dkab315","article-title":"Treatment efficacy for rectal Neisseria gonorrhoeae: a systematic review and meta-analysis of randomized controlled trials","volume":"76","author":"Lo","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"R19-20260810","doi-asserted-by":"crossref","first-page":"2307\u201320","DOI":"10.1007\/s40121-023-00862-6","article-title":"Efficacy and safety of gepotidacin as treatment of uncomplicated urogenital gonorrhea (EAGLE-1): design of a randomized, comparator-controlled, Phase 3 study","volume":"12","author":"Perry","year":"2023","journal-title":"Infect Dis Ther"},{"key":"R20-20260810","doi-asserted-by":"crossref","first-page":"1332\u201345","DOI":"10.1021\/acsinfecdis.0c00021","article-title":"Zoliflodacin: an oral spiropyrimidinetrione antibiotic for the treatment of neisseria gonorrheae, including multi-drug-resistant isolates","volume":"6","author":"Bradford","year":"2020","journal-title":"ACS Infect Dis"},{"key":"R21-20260810","doi-asserted-by":"crossref","first-page":"ofaf000. P-1251","DOI":"10.1093\/ofid\/ofae631.1433","article-title":"P-1251. pharmacometric analyses to support dose selection of zoliflodacin, a first-in-class oral antibiotic being developed for the treatment of uncomplicated gonorrhea","volume":"12","author":"Bhavnani","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"R22-20260810","doi-asserted-by":"crossref","first-page":"1221\u201328","DOI":"10.1093\/jac\/dkab024","article-title":"High susceptibility to zoliflodacin and conserved target (GyrB) for zoliflodacin among 1209 consecutive clinical Neisseria gonorrhoeae isolates from 25 European countries, 2018","volume":"76","author":"Unemo","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"R23-20260810","doi-asserted-by":"crossref","first-page":"626\u201329","DOI":"10.3343\/alm.2024.0522","article-title":"In-vitro activities of zoliflodacin and solithromycin against Neisseria gonorrhoeae isolates from Korea","volume":"45","author":"Roh","year":"2025","journal-title":"Ann Lab Med"},{"key":"R24-20260810","doi-asserted-by":"crossref","first-page":"147\u201360","DOI":"10.1016\/S0140-6736(25)01953-1","article-title":"Zoliflodacin versus ceftriaxone plus azithromycin for treatment of uncomplicated urogenital gonorrhoea: an international, randomised, controlled, open-label, Phase 3, non-inferiority clinical trial","volume":"407","author":"Luckey","year":"2026","journal-title":"Lancet"},{"key":"R25-20260810","doi-asserted-by":"crossref","first-page":"11827","DOI":"10.1038\/srep11827","article-title":"Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases","volume":"5","author":"Basarab","year":"2015","journal-title":"Sci Rep"},{"key":"R26-20260810","first-page":"915346","article-title":"Pharmacodynamic evaluation of zoliflodacin treatment of Neisseria gonorrhoeae strains with amino acid substitutions in the zoliflodacin target gyrb using a dynamic hollow fiber infection model","volume":"13","author":"Jacobsson","year":"2022","journal-title":"Front Pharmacol"},{"key":"R27-20260810","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1071\/SH19034","article-title":"New treatment options for Neisseria gonorrhoeae in the era of emerging antimicrobial resistance","volume":"16","author":"Lewis","year":"2019","journal-title":"Sexual Health"},{"key":"R28-20260810","first-page":"36\u201350","article-title":"Combatting antimicrobial-resistant Neisseria gonorrhoeae: new antibiotics and the pipeline of antigonococcal therapeutics","volume":"39","author":"Ram","year":"2026","journal-title":"Curr Opin Infect Dis"}],"container-title":["Annals of Medicine &amp; Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000005136","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T11:01:50Z","timestamp":1786359710000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MS9.0000000000005136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/ms9.0000000000005136","relation":{},"ISSN":["2049-0801"],"issn-type":[{"value":"2049-0801","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"assertion":[{"value":"2026-02-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}